Teva chief commits to a broad offering

Teva will continue to offer a comprehensive portfolio of both standard and complex generics, as well as biosimilars, as it seeks to defend its position as the world’s leading generics supplier, according to Kåre Schultz, who took charge as the Israeli group’s chief executive officer in November last year.